title: Novel therapeutics for gastro-esophageal reflux symptoms.
abstract: Approximately 20-30% of patients with gastro-esophageal reflux symptoms report inadequate symptom relief while on proton-pump inhibitor therapy. The mechanisms involved are failure of the antireflux barrier (transient lower esophageal sphincter relaxations), high proximal extent of the refluxate, esophageal hypersensitivity and impaired mucosal integrity. Persisting acid or nonacid reflux can be demonstrated in 40-50% of cases, suggesting that there is room for antireflux therapy in these patients. New antireflux compounds have been shown to decrease the occurrence of transient lower esophageal sphincter relaxations. The most promising classes of compounds are GABA type B agonists and metabotropic glutamate receptor 5 antagonists, which can reduce both reflux episodes and symptoms, but the development of these compounds has been abandoned for either safety issues or lack of efficacy. Esophageal hypersensitivity and impaired mucosal integrity may prove to be relevant therapeutic targets in the future.
authors.affiliation: CHU Bordeaux, Saint André Hospital, Gastroenterology Department, Bordeaux, F-33075, France. frank.zerbib@chu-bordeaux.fr
authors.forename: Frank
authors.initials: F
authors.lastname: Zerbib
authors.forename: Mireille
authors.initials: M
authors.lastname: Simon
mesh_terms: D055808:Drug Discovery; D049630:Esophageal Sphincter, Lower / Q000187:drug effects*; D058786:GABA-B Receptor Agonists / Q000009:adverse effects*; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D058786:GABA-B Receptor Agonists; D054328:Proton Pump Inhibitors; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate